GPT and anemia: Regarding tolerability, subject to the retrospective nature of the study, which may limit the quality of AE reporting, the tolerance profile was generally favorable in our study population, with only 21% experiencing AEs of grade ≥3, with the most common being under encorafenib/cetuximab: arthralgia/myalgia, abdominal pain, nausea/vomiting, anemia, and AST/ALT increase, with incidence rates consistently below 5%, and numerically lower rate of ≥3 AEs in patients treated with encorafenib/cetuximab +/− binimetinib in first- or second-line compared with those treated beyond the second line.